Cargando…

CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the most lethal tumour worldwide. Copine 1 (CPNE1) was identified as a novel oncogene in NSCLC in our previous study. However, its specific function and relative mechanisms remain poorly understood. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Anqi, Yang, Wen, Li, Yue, Zhang, Yang, Zhou, Jieqi, Zhang, Ruochen, Zhang, Weijie, Zhu, Jianjie, Zeng, Yuanyuan, Liu, Zeyi, Huang, Jian-an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802424/
https://www.ncbi.nlm.nih.gov/pubmed/35101055
http://dx.doi.org/10.1186/s12964-021-00818-8
_version_ 1784642667299209216
author Wang, Anqi
Yang, Wen
Li, Yue
Zhang, Yang
Zhou, Jieqi
Zhang, Ruochen
Zhang, Weijie
Zhu, Jianjie
Zeng, Yuanyuan
Liu, Zeyi
Huang, Jian-an
author_facet Wang, Anqi
Yang, Wen
Li, Yue
Zhang, Yang
Zhou, Jieqi
Zhang, Ruochen
Zhang, Weijie
Zhu, Jianjie
Zeng, Yuanyuan
Liu, Zeyi
Huang, Jian-an
author_sort Wang, Anqi
collection PubMed
description BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the most lethal tumour worldwide. Copine 1 (CPNE1) was identified as a novel oncogene in NSCLC in our previous study. However, its specific function and relative mechanisms remain poorly understood. METHODS: The biological role of CPNE1 and RACK1 in NSCLC was investigated using gene expression knockdown and overexpression, cell proliferation assays, clonogenic assays, and Transwell assays. The expression levels of CPNE1, RACK1 and other proteins were determined by western blot analysis. The relationship between CPNE1 and RACK1 was predicted and investigated by mass spectrometry analysis, immunofluorescence staining, and coimmunoprecipitation. NSCLC cells were treated with a combination of a MET inhibitor and gefitinib in vitro and in vivo. RESULTS: We found that CPNE1 facilitates tumorigenesis in NSCLC by interacting with RACK1, which further induces activation of MET signaling. CPNE1 overexpression promoted cell proliferation, migration, invasion and MET signaling in NSCLC cells, whereas CPNE1 knockdown produced the opposite effects. In addition, the suppression of the enhancing effect of CPNE1 overexpression on tumorigenesis and MET signaling by knockdown of RACK1 was verified. Moreover, compared to single-agent treatment, dual blockade of MET and EGFR resulted in enhanced reductions in the tumour volume and downstream signaling in vivo. CONCLUSIONS: Our findings show that CPNE1 promotes tumorigenesis by interacting with RACK1 and activating MET signaling. The combination of a MET inhibitor with an EGFR-TKI attenuated tumour growth more significantly than either single-drug treatment. These findings may provide new insights into the biological function of CPNE1 and the development of novel therapeutic strategies for NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-021-00818-8.
format Online
Article
Text
id pubmed-8802424
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88024242022-02-02 CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway Wang, Anqi Yang, Wen Li, Yue Zhang, Yang Zhou, Jieqi Zhang, Ruochen Zhang, Weijie Zhu, Jianjie Zeng, Yuanyuan Liu, Zeyi Huang, Jian-an Cell Commun Signal Research BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and the most lethal tumour worldwide. Copine 1 (CPNE1) was identified as a novel oncogene in NSCLC in our previous study. However, its specific function and relative mechanisms remain poorly understood. METHODS: The biological role of CPNE1 and RACK1 in NSCLC was investigated using gene expression knockdown and overexpression, cell proliferation assays, clonogenic assays, and Transwell assays. The expression levels of CPNE1, RACK1 and other proteins were determined by western blot analysis. The relationship between CPNE1 and RACK1 was predicted and investigated by mass spectrometry analysis, immunofluorescence staining, and coimmunoprecipitation. NSCLC cells were treated with a combination of a MET inhibitor and gefitinib in vitro and in vivo. RESULTS: We found that CPNE1 facilitates tumorigenesis in NSCLC by interacting with RACK1, which further induces activation of MET signaling. CPNE1 overexpression promoted cell proliferation, migration, invasion and MET signaling in NSCLC cells, whereas CPNE1 knockdown produced the opposite effects. In addition, the suppression of the enhancing effect of CPNE1 overexpression on tumorigenesis and MET signaling by knockdown of RACK1 was verified. Moreover, compared to single-agent treatment, dual blockade of MET and EGFR resulted in enhanced reductions in the tumour volume and downstream signaling in vivo. CONCLUSIONS: Our findings show that CPNE1 promotes tumorigenesis by interacting with RACK1 and activating MET signaling. The combination of a MET inhibitor with an EGFR-TKI attenuated tumour growth more significantly than either single-drug treatment. These findings may provide new insights into the biological function of CPNE1 and the development of novel therapeutic strategies for NSCLC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-021-00818-8. BioMed Central 2022-01-31 /pmc/articles/PMC8802424/ /pubmed/35101055 http://dx.doi.org/10.1186/s12964-021-00818-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Anqi
Yang, Wen
Li, Yue
Zhang, Yang
Zhou, Jieqi
Zhang, Ruochen
Zhang, Weijie
Zhu, Jianjie
Zeng, Yuanyuan
Liu, Zeyi
Huang, Jian-an
CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway
title CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway
title_full CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway
title_fullStr CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway
title_full_unstemmed CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway
title_short CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway
title_sort cpne1 promotes non-small cell lung cancer progression by interacting with rack1 via the met signaling pathway
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802424/
https://www.ncbi.nlm.nih.gov/pubmed/35101055
http://dx.doi.org/10.1186/s12964-021-00818-8
work_keys_str_mv AT wanganqi cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT yangwen cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT liyue cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT zhangyang cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT zhoujieqi cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT zhangruochen cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT zhangweijie cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT zhujianjie cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT zengyuanyuan cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT liuzeyi cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway
AT huangjianan cpne1promotesnonsmallcelllungcancerprogressionbyinteractingwithrack1viathemetsignalingpathway